Rizatriptan

All congenital malformations (majors, minors, majors and minors, or unspecified)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S3583
R7180		 Nezvalová-Henriksen (Control unexposed, disease free), 2013 Congenital malformations (any) 1st trimester population based cohort retrospective unexposed, disease free excluded Adjustment: Yes 0.85 [0.50;1.45]
excluded (control group) 		14/310   9,136/178,565 9,150 310
ref
S3584
R7197		 Nezvalová-Henriksen (Control unexposed, sick), 2013 Congenital malformations (any) 1st trimester population based cohort retrospective unexposed, sick Adjustment: No 0.71 [0.34;1.46] C 14/310   17/271 31 310
ref
S3505
R6840		 Källén (control exposed to ergots), 2011 Any congenital malformations 1st trimester population based cohort propective exposed to other treatment, sick excluded Adjustment: No 1.12 [0.47;2.70] C
excluded (control group) 		7/157   21/527 28 157
ref
S3498
R6823		 Källén (control unexposed, disease free), 2011 Any congenital malformations 1st trimester population based cohort propective unexposed, disease free Adjustment: No 1.01 [0.40;2.08] 7/157   56,759/1,229,901 56,766 157
ref
Total 2 studies 0.83 [0.48;1.43] 56,797 467
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Nezvalová-Henriksen (Control unexposed, sick), 2013Nezvalová-Henriksen, 2013 1 0.71[0.34; 1.46]3131056%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Källén (control unexposed, disease free), 2011Källén, 2011 2 1.01[0.40; 2.08]56,76615744%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 0.83[0.48; 1.43]56,7974670.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Control unexposed, sick; 2: control unexposed, disease free;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.83[0.48; 1.43]56,7974670%NANezvalová-Henriksen (Control unexposed, sick), 2013 Källén (control unexposed, disease free), 2011 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.01[0.44; 2.30]56,766157 -NAKällén (control unexposed, disease free), 2011 1 unexposed, sickunexposed, sick 0.71[0.34; 1.46]31310 -NANezvalová-Henriksen (Control unexposed, sick), 2013 1 Tags Adjustment   - No  - No 0.83[0.48; 1.43]56,7974670%NANezvalová-Henriksen (Control unexposed, sick), 2013 Källén (control unexposed, disease free), 2011 2 All studiesAll studies 0.83[0.48; 1.43]56,7974670%NANezvalová-Henriksen (Control unexposed, sick), 2013 Källén (control unexposed, disease free), 2011 20.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 3505, 3583

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 0.89[0.57; 1.40]65,9164670%NANezvalová-Henriksen (Control unexposed, disease free), 2013 Källén (control unexposed, disease free), 2011 2 unexposed, sick controlsunexposed, sick controls 0.71[0.34; 1.46]31310 -NANezvalová-Henriksen (Control unexposed, sick), 2013 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.12[0.47; 2.70]28157 -NAKällén (control exposed to ergots), 2011 10.510.01.0